ArticleComputational and structural biotechnology journal2026
The Redesign of the Molecular Scaffold of Viral Ion Channel Blockers.
Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of rapidly mutating viruses poses growing challenges for drug developers in the fight against antiviral resistance. Viral ion channels generally have low mutation rates and are therefore considered emerging targets for a sustainable solution to the problem of resistance. This study reports the redesign of scaffolds for drug candidates targeting viral ion channels. The redesign was powered by a combination of a computational docking protocol that accounts for water molecules (HydroDock) and a subsequent quantum mechanics-based scoring (QMH-L) of the drug candidates. Extending the antiviral amantadine led to new compounds that better match the alternating hydrophobic and hydrophilic patterns of the inner walls of ion channels-a common feature across many viruses. Simplifying the structure yielded a cyclohexylamine-based minimalist scaffold that demonstrates improved antiviral activity compared to other agents such as amantadine and arterolane. SARS-CoV-2 variants served as test systems in laboratory experiments. The new molecular scaffolds presented here provide a strong foundation for designing potent viral ion channel blockers, helping to fill the drug pipeline.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.